Gilead Sciences (NASDAQ:GILD) CEO Sells $15,611,400.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the sale, the chief executive officer owned 566,698 shares of the company’s stock, valued at $76,504,230. This trade represents a 16.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Daniel Patrick O’day also recently made the following trade(s):

• On Monday, December 29th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $124.83, for a total transaction of $1,248,300.00.
• On Friday, November 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $126.54, for a total transaction of $1,265,400.00.
• On Tuesday, October 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00.

Gilead Sciences Stock Up 1.4%

Shares of GILD traded up $1.85 during midday trading on Monday, hitting $137.78. The stock had a trading volume of 10,011,170 shares, compared to its average volume of 5,997,583. The firm has a market cap of $170.94 billion, a price-to-earnings ratio of 16.60, a price-to-earnings-growth ratio of 0.71 and a beta of 0.33. The company has a 50 day simple moving average of $123.98 and a two-hundred day simple moving average of $118.71. Gilead Sciences, Inc. has a twelve month low of $93.10 and a twelve month high of $138.03. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.3%. Gilead Sciences’s payout ratio is 48.99%.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors have recently made changes to their positions in the company. Norges Bank acquired a new position in shares of Gilead Sciences during the second quarter worth $2,150,268,000. Ameriprise Financial Inc. raised its position in Gilead Sciences by 397.6% in the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after purchasing an additional 5,392,191 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Gilead Sciences by 3,763.8% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock valued at $518,368,000 after purchasing an additional 4,113,999 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after purchasing an additional 3,394,330 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Gilead Sciences by 164.4% during the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after purchasing an additional 2,169,266 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Needham & Company LLC upped their target price on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Wells Fargo & Company boosted their price target on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Morgan Stanley dropped their price objective on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 13th. UBS Group raised their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday. Finally, Sanford C. Bernstein set a $135.00 price target on shares of Gilead Sciences and gave the stock an “outperform” rating in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $134.52.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.